Literature DB >> 18307725

Examination of chromosome 7p22 candidate genes RBaK, PMS2 and GNA12 in familial hyperaldosteronism type II.

Y W A Jeske1, A So, L Kelemen, N Sukor, C Willys, B Bulmer, R D Gordon, D Duffy, M Stowasser.   

Abstract

1. There are two types of familial hyperaldosteronism (FH): FH-I and FH-II. FH-I is caused by a hybrid CYP11B1/CYP11B2 gene mutation. The genetic cause of FH-II, which is more common, is unknown. Adrenal hyperplasia and adenomas are features. We previously reported linkage of FH-II to a approximately 5 Mb region on chromosome 7p22. We subsequently reported finding no causative mutations in the retinoblastoma-associated Kruppel-associated box gene (RBaK), a candidate at 7p22 involved in tumorigenesis and cell cycle control. 2. In the current study we investigated RBaK regulatory regions and two other candidate genes: postmeiotic segregation increased 2 (PMS2, involved in DNA mismatch repair and tumour predisposition) and guanine nucleotide-binding protein alpha-12 (GNA12, a transforming oncogene). 3. The GNA12 and PMS2 genes were examined in two affected (A1, A2) and two unaffected (U1, U2) subjects from a large 7p22-linked FH-II family (family 1). No mutations were found. 4. The RBaK and PMS2 distal promoters were sequenced to -2150 bp from the transcription start site for RBaK and-2800 bp for PMS2. Five unreported single nucleotide polymorphisms (SNPs) were found in subjects A1, A2 but not in U1 or U2; A(-2031 bp)T, T(-2030 bp)G, G(-834 bp)C, C(-821 bp)G in RBaK and A(-876 bp)G in PMS2. Additional affected and unaffected subjects from family 1 and from two other 7p22-linked FH-II families and 58 unrelated normotensive control subjects were genotyped for these SNPs. 5. The five novel SNPs were found to be present in a significant proportion of normotensive controls. The four RBaK promoter SNPs were found to be in linkage disequilibrium in the normal population. The RBaK promoter (-)2031T/2030G/834C/821T allele was found to be in linkage disequilibrium with the causative mutation in FH-II family 1, but not in families 2 and 3. The PMS2 promoter (-)876G allele was also found to be linked to affected phenotypes in family 1. 6. The RBaK and PMS2 promoter SNPs alter the binding sites for several transcription factors. Although present in the normal population, it is possible that the RBaK (-)2031T/2030G/834C/821T and PMS2 (-)876G alleles may have functional roles contributing to the FH-II phenotype in family 1.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18307725     DOI: 10.1111/j.1440-1681.2008.04882.x

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  9 in total

Review 1.  Pathogenesis of Familial Hyperaldosteronism Type II: New Concepts Involving Anion Channels.

Authors:  Michael Stowasser; Martin Wolley; Aihua Wu; Richard D Gordon; Julia Schewe; Gabriel Stölting; Ute I Scholl
Journal:  Curr Hypertens Rep       Date:  2019-04-04       Impact factor: 5.369

2.  Primary Aldosteronism and ARMC5 Variants.

Authors:  Mihail Zilbermint; Paraskevi Xekouki; Fabio R Faucz; Annabel Berthon; Alexandra Gkourogianni; Marie Helene Schernthaner-Reiter; Maria Batsis; Ninet Sinaii; Martha M Quezado; Maria Merino; Aaron Hodes; Smita B Abraham; Rossella Libé; Guillaume Assié; Stéphanie Espiard; Ludivine Drougat; Bruno Ragazzon; Adam Davis; Samson Y Gebreab; Ryan Neff; Electron Kebebew; Jérôme Bertherat; Maya B Lodish; Constantine A Stratakis
Journal:  J Clin Endocrinol Metab       Date:  2015-03-30       Impact factor: 5.958

3.  ARMC5 is not implicated in familial hyperaldosteronism type II (FH-II).

Authors:  S M C De Sousa; M Stowasser; J Feng; A W Schreiber; P Wang; C N Hahn; R D Gordon; D J Torpy; H S Scott; L Gagliardi
Journal:  J Hum Hypertens       Date:  2017-10-12       Impact factor: 3.012

Review 4.  Epigenetics and hypertension.

Authors:  Richard M Millis
Journal:  Curr Hypertens Rep       Date:  2011-02       Impact factor: 5.369

Review 5.  Primary aldosteronism: from bench to bedside.

Authors:  Norlela Sukor
Journal:  Endocrine       Date:  2011-11-01       Impact factor: 3.633

6.  A novel form of human mendelian hypertension featuring nonglucocorticoid-remediable aldosteronism.

Authors:  David S Geller; Junhui Zhang; Max V Wisgerhof; Cedric Shackleton; Michael Kashgarian; Richard P Lifton
Journal:  J Clin Endocrinol Metab       Date:  2008-05-27       Impact factor: 5.958

7.  Androgen-induced miR-135a acts as a tumor suppressor through downregulating RBAK and MMP11, and mediates resistance to androgen deprivation therapy.

Authors:  Xuechao Wan; Honglei Pu; Wenhua Huang; Shu Yang; Yalong Zhang; Zhe Kong; Zhuoran Yang; Peiqing Zhao; Ao Li; Tao Li; Yao Li
Journal:  Oncotarget       Date:  2016-08-09

8.  Phosphodiesterase 2A and 3B variants are associated with primary aldosteronism.

Authors:  Marcela Rassi-Cruz; Andrea G Maria; Fabio R Faucz; Edra London; Leticia A P Vilela; Lucas S Santana; Anna Flavia F Benedetti; Tatiana S Goldbaum; Fabio Y Tanno; Vitor Srougi; Jose L Chambo; Maria Adelaide A Pereira; Aline C B S Cavalcante; Francisco C Carnevale; Bruna Pilan; Luiz A Bortolotto; Luciano F Drager; Antonio M Lerario; Ana Claudia Latronico; Maria Candida B V Fragoso; Berenice B Mendonca; Maria Claudia N Zerbini; Constantine A Stratakis; Madson Q Almeida
Journal:  Endocr Relat Cancer       Date:  2021-01       Impact factor: 5.678

Review 9.  Molecular Mechanisms of Primary Aldosteronism.

Authors:  Sergei G Tevosian; Shawna C Fox; Hans K Ghayee
Journal:  Endocrinol Metab (Seoul)       Date:  2019-12
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.